Dubuquoy Laurent, Dharancy Sébastien, Nutten Sophie, Pettersson Sven, Auwerx Johan, Desreumaux Pierre
Equipe Propre INSERM 0114 sur la Physiopathologie des Maladies Inflammatoires Intestinales, Centre Hospitalier Universitaire, Lille, France.
Lancet. 2002 Nov 2;360(9343):1410-8. doi: 10.1016/S0140-6736(02)11395-X.
The peroxisome proliferator-activated receptor gamma (PPARgamma) and its partner the retinoid X receptor (RXR) are two nuclear receptors that are expressed mainly in adipose tissue and which have a role in lipid metabolism and insulin sensitisation. New sites of PPARgamma/RXR expression have been described, especially in the intestinal tract, pancreas, and liver. Concomitantly, new functions have been attributed to this heterodimer in regulation of inflammation, by its inhibition of nuclear factor (NF)-kappaB and via stress-kinase pathways. These new sites and functions of PPARgamma/RXR have led to novel ideas about pathophysiology of different inflammatory digestive diseases and to development of innovative treatment strategies with PPARgamma activators.
过氧化物酶体增殖物激活受体γ（PPARγ）及其伴侣视黄酸X受体（RXR）是两种主要在脂肪组织中表达的核受体，它们在脂质代谢和胰岛素敏感性方面发挥作用。PPARγ/RXR的新表达位点已被描述，尤其是在肠道、胰腺和肝脏中。与此同时，这种异二聚体通过抑制核因子（NF）-κB和应激激酶途径，在炎症调节中具有了新的功能。PPARγ/RXR的这些新位点和功能引发了关于不同炎症性消化系统疾病病理生理学的新观点，并推动了使用PPARγ激活剂的创新治疗策略的发展。
